AnHorn Medicines announces AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I clinical trial in the United States. The first subject was dosed this week, marking a major milestone in the development of this innovative therapy.
News
AnHorn Medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for AH-001 novel protein degrader program. This IND marks a significant milestone for the company, being its first regulatory achievement within just four years of its inception.
AnHorn Medicines a AI-based drug development platform focused on creating new drugs through protein degradation, has been invited to present its latest research at the NVIDIA AI Summit on June 5 in Taipei, Taiwan.
Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.
Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.
After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...
We are proud to announce the publication of our latest peer-reviewed paper in ACS Omega. The new approach accelerates hit discovery, increases the chances of finding effective drug candidates.
This paper highlights the transformative potential of our deep neural network, AIMLinker, in the field of drug discovery for PROTAC design...
AnHorn Medicines, as one of the innovators in the field of Targeted Protein Degradation, we have commitment to identify novel E3 enzymes with a clear disease involvement to expand our target coverage.
AnHorn Medicines participated NBRP DEMO DAY to show our one-year progress in research and make connections with investors, global pharma R&D experts, talents, and partners in this field....
We are moving forward to Artificial Intelligence Drug Discovery. The AI-enabled AIMCADD® platform helps us to identify new targets and treatments easier, and better....
AnHorn Medicines’s achievements in 2020, including the smooth establishment for research, operation and finance that support us for considerable progress in 2021...
